PULMONX CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
PULMONX CORPORATION (LUNG) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $17.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-03-10
- PULMONX CORPORATION share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2022-03-31 was $2.70M.
- PULMONX CORPORATION share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $17.40M, a 16.00% increase from fiscal 2024.
- PULMONX CORPORATION share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $15.00M, a 30.88% decline from fiscal 2023.
- PULMONX CORPORATION share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $21.70M, a 40.00% increase from fiscal 2022.
- PULMONX CORPORATION share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $15.50M, a 86.75% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|
| 2025-12-31 | $17.40M 10-K · filed 2026-03-10 | |
| 2024-12-31 | $15.00M 10-K · filed 2026-03-10 | |
| 2023-12-31 | $21.70M 10-K · filed 2025-02-25 | |
| 2022-12-31 | $15.50M 10-K · filed 2024-02-27 | |
| 2022-03-31 | $2.70M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $8.30M 10-K · filed 2023-03-01 | |
| 2020-12-31 | $1.90M 10-K · filed 2022-03-01 | |
| 2019-12-31 | $300.00K 10-K · filed 2021-03-15 | |
| 2018-12-31 | $400.00K 10-K · filed 2021-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |
| RenovoRx, Inc. (RNXT) | United States | $0.076B | -3.62 |
| Microbot Medical Inc. (MBOT) | $0.089B | -7.97 | |
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| Spectral AI, Inc. (MDAI) | United States | $0.052B |